Alexion will pay $610mm plus earn-outs to buy Enobia
Executive Summary
Public biotech Alexion Pharmaceuticals Inc. is acquiring closely held Enobia Pharma Inc. (developing enzyme replacement therapies for bone and metabolic disorders) for $610mm in cash and up to $470mm in earn-outs based on regulatory and sales goals.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice